Latest Health News

Archer Materials has achieved a significant milestone by integrating its graphene-based sensors with silicon readout circuitry, paving the way for a compact, at-home potassium testing device aimed at chronic kidney disease management.

Aroa Biosurgery has reported FY25 results that exceed revenue guidance and deliver a positive normalised EBITDA, setting the stage for ambitious growth and reimbursement expansion in FY26.

HITIQ has secured a three-year deal with AFL Barwon to promote its PROTEQT smart mouthguard across regional Victoria, enhancing concussion management in community sports.

Avecho Biotechnology has received $1.66 million from the Australian Government’s R&D Tax Incentive, reinforcing its commitment to a pivotal Phase III trial for its CBD-based insomnia treatment and accelerating its commercial ambitions.

Epsilon Healthcare has emerged from Administration, securing expanded medicinal cannabis manufacturing permits and launching a new pharmacy brand as part of a strategic turnaround and growth plan.

Emyria reports sustained six-month improvements in treatment-resistant PTSD patients and announces a strategic research collaboration with Australian National University to advance mental health care models.

Atomo Diagnostics has landed a significant $450,000 order to supply HIV self-tests for a federally funded Australian program aimed at increasing at-home testing among high-risk groups.

Talius has deepened its partnership with Silverchain Group to pilot an AI voice assistant aimed at transforming home aged care services, starting with appointment scheduling in Western Australia and eyeing a national rollout.

Lumos Diagnostics has secured Medicare reimbursement for its FebriDx test from a sixth Medicare Administrative Contractor, covering over 85% of US Medicare payment regions. This milestone advances the company’s commercialisation efforts in the US healthcare market.

PainChek Limited has secured a pivotal reseller and integration deal with Eldermark Software, positioning its AI-driven pain assessment app for a major US market rollout pending FDA approval.

RPMGlobal Holdings has announced a 12-month extension to its on-market share buy-back program, adding up to 11 million shares to be repurchased. This move underscores the company’s confidence in its valuation and capital management strategy.

Recce Pharmaceuticals has secured a significant patent acceptance in China for its RECCE® anti-infectives, broadening its intellectual property footprint in the world’s second-largest pharmaceutical market.